Tests and monitoring tools
Biomarker articles covering signals used to study, predict, monitor, or measure Crohn's disease and IBD activity or treatment response. Monitoring context emphasizes diagnosis, follow-up, disease activity, treatment response, and care decisions.
Page 2 of 4 · 190 articles
PSC commonly co-occurs with IBD in children; understanding clinical phenotypes and reliable monitoring tools helps families and clinicians track disease and plan follow-up.
A blood biomarker that tracks both symptoms and endoscopic inflammation could help with noninvasive monitoring of ulcerative colitis activity and reduce reliance on invasive procedures if validated.
Postoperative recurrence is common after intestinal resection for Crohn's disease, but clinicians currently lack reliable molecular biomarkers or validated models to predict who will relapse.
Biopsy-based keratin patterns might help distinguish IBD, microscopic colitis, and IBS—conditions that can look similar clinically—so this could improve diagnostic accuracy if validated.
The paper suggests that the same herbal formula can produce different absorbed components and target interactions depending on oral versus colonic delivery, which could influence therapeutic effects in ulcerative colitis...
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
If true, using infliximab drug-level modeling plus routine blood tests could help predict who has mucosal healing without immediate endoscopy, potentially reducing invasive procedures and improving monitoring for people...
The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and...
A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.
Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve...
Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.
Identifies a stromal-cell subset marked by TIMP1 that may play a role in UC pathogenesis and might serve as a candidate biomarker or therapeutic target; useful for researchers and clinicians following emerging...
This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.
This study links genetic variation in fatty-acid–desaturase genes with membrane PUFA profiles and inflammatory markers in Crohn’s disease. If replicated, erythrocyte desaturase indices could become integrative biomarkers...
Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.
This study reports a non-invasive fluorescence probe that detects a reactive nitrogen species (peroxynitrite) linked to intestinal inflammation and shows signal changes in cells, animal models, and mouse feces — a...
If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...
Non-invasive, portable tests that can track inflammation more frequently could help patients and clinicians monitor disease activity between clinic visits and guide treatment decisions without repeated invasive...
People with IBD are at higher risk for colorectal cancer; identifying stromal genes that track inflammation-driven EMT could help researchers find biomarkers or targets that explain how chronic inflammation promotes...
A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...
Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...
Protease and serpin activity affect the gut barrier, immunity, and microbial ecology—processes central to IBD. Integrating these pathways could help identify biomarkers or targets that explain why IBD varies between...
This narrative review surveys novel biomarkers and therapeutic strategies for adult IBD, topics that could affect diagnosis, monitoring, and future treatment options for people with Crohn's disease or ulcerative colitis.
Researchers are investigating circRNAs as potential biomarkers and therapeutic targets in IBD because they may help explain disease mechanisms and lead to better diagnostics or treatments in the future.
The study identifies distinct fecal bile acid signatures in CRC versus UC that might help develop noninvasive tests to distinguish malignancy from chronic inflammatory disease of the colon.
The study provides a more rigorous, leakage-free machine-learning analysis of a major IBD microbiome cohort and proposes reproducible microbial and metabolic pathway candidates that could eventually help IBD diagnosis or...
Distinguishing acute infectious gastroenteritis from new‑onset IBD can be clinically challenging. Faecal biomarkers that help tell these apart could speed correct diagnosis and treatment and avoid unnecessary...
Patients with UC who appear healed on endoscopy can still relapse; a biopsy-based model could help separate lower- and higher-risk patients and guide monitoring or research enrollment.
FABP2 is presented as a sensitive biomarker of intestinal mucosal injury and a possible contributor to IBD mechanisms; if validated, it could improve disease monitoring and suggest new therapeutic targets.
Researchers identified molecular features of a proposed “ferro‑aging” state in UC and nominated CHST15 and MSN as biomarkers, which could help understand disease biology and point to new experimental targets for therapy...
The review summarizes how extracellular vesicles (EVs) shape immune responses and barrier repair in the gut and discusses their potential as accessible biomarkers and as vehicles for precise IBD therapies — topics that...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...
A strategic, pediatric-focused research agenda helps target studies where children with IBD and related conditions most need better diagnostics, biomarkers, and treatments. Prioritizing multi-center registries and...
Non-invasive, inexpensive blood-derived ratios could offer easier, more frequent assessment of IBD activity than repeat endoscopy. This study evaluates several such ratios (CAR, PAR, NLR, FAR, Hb/CRP) against clinical...
Non-invasive biomarkers can help detect and monitor IBD activity, distinguish IBD from other GI conditions, and potentially predict relapse—tools that may reduce need for invasive tests.
Researchers present a small platelet-related gene signature (TRIM22, TIMP1, RAC2) that may help understand UC biology and point toward blood-based biomarkers. If validated further, such markers might aid noninvasive...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect...
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
